Trial Profile
A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 13 Jul 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Oleclumab (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Ductal carcinoma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors AstraZeneca; MedImmune
- 22 Feb 2023 Planned End Date changed from 20 Jan 2023 to 9 Jun 2023.
- 20 Apr 2022 Planned End Date changed from 21 Jan 2022 to 20 Jan 2023.
- 29 Jun 2021 Planned End Date changed from 22 Jan 2021 to 21 Jan 2022.